Rosa M Giraldez-Perez | Intracellular Transport Systems | Innovative Research Award

Prof. Dr. Rosa M Giraldez-Perez | Intracellular Transport Systems | Innovative Research Award

University or Cordoba | Spain

Rosa María Giráldez-Pérez is a researcher in the fields of nanotechnology, nanomedicine, physiology, and neuroscience whose scientific contributions focus on the design and application of nanomaterials for therapeutic purposes. Her work has addressed innovative strategies such as gold nanosystems functionalized with antibiotics or anticancer drugs, the development of nanocarriers for leukemia, prostate, liver, and lung cancer treatments, as well as nanoparticle-based approaches to prevent antibiotic resistance. She has also contributed to research in obesity therapy through nanosystems targeting metabolic regulation and in neuroscience through studies on oxidative stress and fragile X syndrome. Her research output includes 81 scientific documents, which have accumulated 911 citations and reflect an h-index of 13, demonstrating both productivity and impact in her field. A significant portion of her publications are in high-impact journals indexed in the Journal Citation Reports (JCR), and several list her as first or senior author, highlighting her leading role in collaborative projects. By integrating expertise from cellular biology, physiology, and nanoscience, her work advances translational biomedical research and offers potential therapeutic solutions for cancer, infectious diseases, metabolic disorders, and neurological conditions.

Profiles: Orcid | Scopus

Featured Publications:

Giráldez-Pérez, R. M., Grueso, E. M., Montero-Hidalgo, A. J., Muriana-Fernández, C., Kuliszewska, E., Luque, R. M., & Prado-Gotor, R. (2025). Daunomycin nanocarriers with high therapeutic payload for the treatment of childhood leukemia. Pharmaceutics, 17(9), 1236.

De Diego-Otero, Y., El Bekay, R., García-Guirado, F., Sánchez-Salido, L., & Giráldez-Pérez, R. M. (2024). Apocynin, a selective NADPH oxidase (Nox2) inhibitor, ameliorates behavioural and learning deficits in the fragile X syndrome mouse model. Biomedicines, 12(2887).

Lhamyani, S., Gentile, A. M., Mengual-Mesa, M., Grueso, E., Giráldez-Pérez, R. M., Fernandez-Garcia, J. C., … El Bekay, R. (2024). Au@16-pH-16/miR-21 mimic nanosystem: An efficient treatment for obesity through browning and thermogenesis induction. Biomedicine & Pharmacotherapy, 171, 116104.

Giráldez-Pérez, R. M., Grueso-Molina, E. M., Carbonero-Martínez, A., Álvarezmárquez, J., Kuliszewska, E., Gordillo-Macías, M., & Prado-Gotor, R. (2023). Synergistic antibacterial effects of amoxicillin and gold nanoparticles: A therapeutic option to combat antibiotic resistance. Antibiotics, 12(8), 81275.

Giráldez-Pérez, R. M., Grueso, E., Montero-Hidalgo, A. J., Luque, R. M., Carnerero, J. M., Kuliszewska, E., & Prado-Gotor, R. (2022). Gold nanosystems covered with doxorubicin/DNA complexes: A therapeutic target for prostate and liver cancer. International Journal of Molecular Sciences, 23(24), 15575.

Giráldez-Pérez, R. M., Grueso, E. M., Jiménez-Aguayo, R., Carbonero, A., González-Bravo, M., Kuliszewska, E., & Prado-Gotor, R. (2022). Use of nanoparticles to prevent resistance to antibiotics: Synthesis and characterization of gold nanosystems based on tetracycline. Pharmaceutics, 14(9), 1941.

Lhamyani, S., Gentile, A. M., Giráldez-Pérez, R. M., et al. (2021). miR-21 mimic blocks obesity in mice: A novel therapeutic option. Molecular Therapy – Nucleic Acids, 26, 401–416. h

Grueso-Molina, E. M., Giráldez-Pérez, R. M., Kuliszewska, E., Guerrero, J. A., & Prado-Gotor, R. (2021). Reversible cationic gemini surfactant-induced aggregation of anionic gold nanoparticles for sensing biomolecules. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 610, 125893.

Gomes, A., Carnerero-Panduro, J. M., Jiménez-Ruiz, A., Grueso-Molina, E. M., Giráldez-Pérez, R. M., & Prado-Gotor, R. (2021). Lysozyme-AuNPs interactions: Determination of binding free energy. Nanomaterials, 11(8), 2139.

Giráldez-Pérez, R. M., Grueso-Molina, E. M., Domínguez-García, I., Pastor-Carrillo, N. M., Kuliszewska, E., & Prado-Gotor, R. (2021). Biocompatible DNA/5-fluorouracil gemini surfactant-functionalized gold nanoparticles as promising vectors in lung cancer therapy. Pharmaceutics, 13(3), 423.

Pryanka Thakur | Dengue | Young Scientist Award

Dr. Pryanka Thakur | Dengue | Young Scientist Award

Dr. Pryanka Thakur | Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh | India

Dr. Pryanka Thakur is a dedicated virologist and Project Research Scientist-I at PGIMER, Chandigarh, working in Professor Sunil Sethi’s laboratory. She earned her Ph.D. in Virology from PGIMER under the mentorship of Professor (Dr.) Radha Kanta Ratho, Dean of PGIMER. Her research revolves around molecular pathogenesis, particularly focusing on viral diseases such as Dengue, COVID-19, Hepatitis E, and emerging zoonotic threats. With numerous high-impact publications and presentations at national and international forums, Dr. Thakur has built a commendable academic and research portfolio. Her work contributes to a deeper understanding of viral mechanisms and their public health implications. She has received accolades like the Young Scientist Award and DST-SERB travel grant, reflecting her potential as a rising star in infectious disease research. Passionate about molecular diagnostics and disease pathogenesis, Dr. Thakur’s academic rigor and commitment position her as a promising candidate for the Research for Young Scientist Award.

Publication Profile: 

Orcid

Scopus

Education:

Dr. Pryanka Thakur completed her Ph.D. in Virology at the prestigious Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, from August 2018 to March 2024. Her thesis, titled “Role of inflammasome and autophagy in the pathogenesis of severity of Dengue fever,” was conducted under the supervision of Professor (Dr.) Radha Kanta Ratho, a leading authority in virology. Her doctoral work explored critical host-pathogen interactions, offering insights into mechanisms influencing disease severity. During this period, she honed her skills in molecular virology, diagnostics, and cellular biology. Her academic foundation is deeply rooted in translational and clinical virology, with particular emphasis on autophagy, inflammasomes, and immunological responses during viral infections. Through her rigorous training and extensive hands-on experience with cutting-edge lab techniques, she emerged as a well-rounded scientist with both technical expertise and conceptual depth in infectious disease research, specifically RNA viruses and M. tuberculosis.

Experience:

Dr. Pryanka Thakur currently serves as a Project Research Scientist-I in the Department of Medical Microbiology, PGIMER, Chandigarh, under the mentorship of Professor Sunil Sethi. Her research has primarily focused on virological and immunological responses to emerging and re-emerging infections. She has extensive experience in molecular biology, cell culture, diagnostics, and bioinformatics, contributing to major national and international research initiatives. During her Ph.D., she contributed significantly to studies on Dengue pathogenesis, SARS-CoV-2 evolution, and the intersection of autophagy and inflammasome activity. Her experience also includes collaboration with clinicians, epidemiologists, and diagnostic labs, showcasing her ability to work in interdisciplinary settings. Beyond lab work, she has actively participated in scientific writing, mentoring junior researchers, and presenting findings at forums like ECCMID and VIROCON. Her track record reflects a strong combination of leadership, innovation, and research integrity—making her a standout young investigator.

Awards and Honors:

Dr. Pryanka Thakur’s excellence in research has been recognized through prestigious accolades. In 2024, she was honored with the Young Scientist Award at the VIROCON 2024 conference held at DRDE, Gwalior, for her impactful Ph.D. research on Dengue virus pathogenesis. Additionally, she secured the highly competitive DST-SERB International Travel Grant to present her work at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark. These honors are a testament to the significance and quality of her research in infectious diseases. Her recognition on both national and international platforms demonstrates her rising reputation within the scientific community. These awards not only validate her current achievements but also underscore her potential for future contributions to global health challenges. Her work continues to resonate with experts in virology, public health, and molecular diagnostics—solidifying her status as a promising candidate for further research awards.

Research Focus:

Dr. Pryanka Thakur’s research is rooted in the pathogenesis, immunology, and molecular biology of emerging infectious diseases. Her Ph.D. research dissected the intricate roles of inflammasome activation and autophagy dysregulation in severe Dengue infections—paving the way for targeted therapies and better clinical outcomes. She also actively investigates RNA viruses, including SARS-CoV-2, Hepatitis E, Monkeypox, Nipah, and avian influenza, exploring their mutation patterns, immune evasion strategies, and pandemic potential. Her recent studies also delve into co-infections (e.g., Dengue and COVID-19 in pregnancy), and the reemergence of known pathogens in the post-pandemic era. Dr. Thakur maintains a special interest in molecular diagnostics, enabling early and accurate disease detection. Her contributions bridge laboratory science with clinical relevance, aiming to develop diagnostic tools and deepen our understanding of host-pathogen dynamics. This interdisciplinary approach positions her to make substantial contributions to the field of translational virology and public health microbiology.

Publications Top Notes: 

  1. Waves and variants of SARS-CoV-2: Understanding the causes and effect of the COVID-19 catastropheInfection, 2022.

  2. Viral Hepatitis E and Chronicity: A growing public health concernFrontiers in Microbiology, 2020.

  3. Monkeypox virus in humans: A concern – Trespassing global boundariesInt J Surg, 2022.

  4. Emergence of novel omicron hybrid variants: BA(x), XE, XD, XF – More than just alphabetsInt J Surg, 2022.

  5. Nipah Outbreak: Beginning of another pandemic in the era of COVID-19 and Zika?Brain Behav Immun, 2021.

  6. Evolutionary dynamics of emergent SARS-CoV-2 variants: Just within a yearImmunome Research, 2021.

  7. Avian influenza revisited: Concerns and constraintsVirusDisease, 2022.

  8. Maternal and perinatal outcome in Dengue and COVID-19 co-infected pregnanciesEur J Obstet Gynecol Reprod Biol, 2023.

  9. Post-COVID-19 era: Re-emergence of known and future (X) viral pathogensVacunas, 2024.

  10.  Paclitaxel production from endophytic Mucor circinelloides from Himalayan Taxus sp.3 Biotech, 2024.

Conclusion:

In conclusion, Dr. Pryanka Thakur is an exceptionally well-qualified candidate for the Research for Young Scientist Award. Her academic rigor, publication excellence, and strong interest in infectious disease pathogenesis make her a standout young researcher. She brings a unique blend of molecular insights and public health relevance to her work, making significant contributions to understanding emerging viral threats. With national recognition and international exposure already under her belt, she is on a clear upward trajectory in academic science. Supporting her at this stage through the Young Scientist Award would not only validate her past contributions but also empower her to lead future advancements in virology, diagnostics, and translational medical research. With minor enhancements in project independence and translational focus, Dr. Thakur is poised to become a future leader in infectious disease research, making her a deserving recipient of this award.

 

Maria Andriolo | Host-Pathogen Interactions | Best Innovation Award

Dr. Maria Andriolo | Host-Pathogen Interactions | Best Innovation Award

Dr. Maria Andriolo, ASP CALTANISSETTA, Italy

Maria Andriolo is a dedicated biomedical researcher and clinical biologist with extensive experience in neuroscience, immunology, and post-traumatic disorders. Her multidisciplinary approach has led to impactful contributions in clinical diagnostics, neurorehabilitation, and infectious disease studies. With decades of experience across leading Italian institutions, she combines clinical insight with scientific rigor. She has served in prestigious roles such as a Member of the State Examination Commission and President of Public Selection Committees. Dr. Andriolo is widely published, collaborating on pioneering studies in fields including brain trauma, sepsis diagnostics, and vaccine immunoresponse. Known for her collaborative spirit and leadership, she also contributes as a conference moderator and educator. Her body of work reflects a deep commitment to translational science that benefits patient care and public health.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Multidisciplinary Research Impact
    Dr. Andriolo’s work spans key medical research areas including:

    • Neurology (e.g., traumatic brain injury, disorders of consciousness)

    • Clinical Biochemistry (e.g., neuron-specific enolase, BDNF, CSF biomarkers)

    • Microbiology & Infectious Diseases (e.g., antimicrobial resistance, sepsis diagnostics)

    • Immunology & Vaccine Response (e.g., post-COVID vaccine serology in healthcare workers)

  2. Innovation with Real-World Impact
    Her studies focus on biomarkers for rapid diagnosis, rehabilitation outcomes, and immune responses, directly translating into improved patient care, particularly in:

    • Post-traumatic brain disorders

    • Early detection of sepsis

    • Infection control strategies

  3. Collaborative and High-Impact Publications

    • Extensive peer-reviewed articles in PubMed-indexed journals like Journal of Neurotrauma, Brain Sciences, Vaccines, and Science Reports.

    • Publications show collaborations with leading national research teams and hospitals.

  4. Scientific Leadership & Recognition

    • Appointed as President of National Selection Committees and State Examiner for Biologist Certification.

    • Served as Moderator at ECM Conferences, further demonstrating peer trust and scientific communication skills.

⚠️ Areas for Improvement:

  1. Lead Authorship and Project Ownership

    • While her publication record is strong, she is mostly listed as co-author. Clear documentation of principal investigator roles, research grants led, or independent innovation patents would further bolster her candidacy.

  2. International Presence

    • A broader international profile (e.g., global conferences, cross-border collaborative studies, citations from non-EU entities) could elevate her global impact.

  3. Recent Innovation Highlights

    • A focused submission highlighting a single groundbreaking innovation (e.g., biomarker panel for TBI prognosis or rapid sepsis tool) would align more clearly with “Best Innovation” award criteria.

🎓 Education:

While the detailed educational background isn’t listed, Maria Andriolo’s professional and scientific achievements imply a robust academic foundation in Biology, Neuroscience, and Clinical Diagnostics, likely culminating in at least a Master’s or Doctorate-level education in Biomedical Sciences. Her involvement as a State Examiner for Biologist Qualification and leader of academic committees suggests a longstanding connection with university-level institutions, particularly the University of Messina. Given her expertise and publication record, it is evident she has received specialized training in neurobiology, molecular genetics, clinical chemistry, and medical microbiology. She has actively participated in ECM-accredited medical conferences, indicating a commitment to continuing professional development. This mix of structured education and applied training positions her as a highly qualified scientific professional.

💼 Professional Experience:

Maria Andriolo holds significant academic and clinical leadership roles. She was appointed in July 2024 as a Member of the State Examination Commission for Biologists at the University of Messina, overseeing professional certifications. In June 2023, she served as President of the Examination Committee for a public selection competition for C1 research staff. She is frequently invited to act as a moderator at ECM-accredited conferences, underscoring her peer recognition in the field. Her expertise spans biomedical research, academic evaluation, and public health diagnostics. Maria’s ability to combine scientific knowledge with regulatory oversight and teaching makes her a valuable contributor to academia and public institutions. Her leadership and participation in national scientific initiatives demonstrate her commitment to innovation, clinical application, and academic excellence.

🔬 Research Focus:

Maria Andriolo’s research is anchored in neuroscience, post-traumatic disorders, biomarkers, and infectious diseases. Her work often centers on patients with disorders of consciousness following trauma, analyzing biomarkers like BDNF, neurofilaments, and amyloid-beta proteins. She is a leading contributor in understanding the neurochemical pathways associated with brain injury and rehabilitation. Maria has also co-authored influential studies on sepsis diagnostics, immune response to COVID-19 vaccines, and antimicrobial resistance. Her research combines laboratory diagnostics with clinical applications, enabling faster diagnoses and more effective treatment strategies. She is known for utilizing multidisciplinary frameworks, involving neurologists, microbiologists, and clinicians to translate science into solutions. This strong translational impact underscores her candidacy for the Best Innovation Award, as she bridges the gap between research and patient-centered innovation.

📚 Publications Top Notes:

  1. 🧠 Reduced neuron-specific enolase levels in chronic severe traumatic brain injury

  2. 🧬 Multidisciplinary approach for the rapid diagnosis of sepsis

  3. 💉 Serological analysis of humoral immune response in Sicilian HCWs post-COVID vaccination

  4. 🧠 Dissociation of CSF amyloid-beta and tau in post-traumatic consciousness disorders

  5. 💉 Staphylococcus aureus in bloodstream infections: frequency & antimicrobial resistance

  6. 🧠 Serum BDNF levels are reduced in disorders of consciousness

  7. 🧠 Six-month outcomes in traumatic consciousness disorders (hemorrhagic/non-hemorrhagic)

  8. 🧠 BDNF Val66Met polymorphism and post-traumatic vegetative state recovery

  9. 💉 Anaphylaxis to streptomycin

  10. 🧠 Prolonged CSF neurofilament light chain increase in traumatic brain patients

🏁 Conclusion:

Maria Andriolo is a highly suitable and deserving candidate for the Research for Best Innovation Award. Her research demonstrates:

  • Exceptional depth in translational neuroscience and diagnostics

  • A strong commitment to multidisciplinary collaboration

  • A clear track record of innovation that impacts both patient outcomes and healthcare protocols

 

 

 

Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Prof. Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Prof. Zhijie Chang, Tsinghua University, China

Professor Zhijie Chang is a distinguished molecular biologist and tenured professor at the School of Medicine and School of Life Sciences, Tsinghua University, Beijing. His research spans cancer signaling pathways, extracellular vesicle-mediated communication, and stem cell therapy, especially in lung diseases and tumor biology. A seasoned scholar, Dr. Chang earned his Ph.D. in Animal Genetics and Breeding before undertaking postdoctoral training at the University of Alabama at Birmingham. He is currently a respected editor of FEBS Letters and a leader in molecular oncology in China. His recent works highlight the role of CREPT, Smad signaling, and macrophage modulation in cancer and fibrosis. Through decades of academic and translational research, he has significantly advanced our understanding of cell communication in disease contexts. With an extensive publication record in top journals, Dr. Chang remains a leading figure in Asia’s biomedical research landscape.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Pioneering Contributions in Cell Communication
    Prof. Chang’s research on CREPT, Smad proteins, NF-κB/Nrf2, and BMP signaling has directly advanced the understanding of how intracellular and intercellular communication impacts disease progression, especially in cancer and pulmonary disorders.

  2. High-Impact Publications
    He has numerous peer-reviewed articles in prestigious journals such as Nature Communications, Molecular Cancer, Signal Transduction and Targeted Therapy, and Journal of Biological Chemistry, many of which explore molecular and cellular communication in cancer and tissue repair.

  3. Translational Focus
    His integration of mesenchymal stem cell therapy, extracellular vesicles, and gene therapy reflects a strong translational approach, applying basic science to therapeutic innovations—a critical criterion for this award.

  4. Scientific Leadership and Mentorship
    As a tenured professor at Tsinghua University and editor at FEBS Letters, Prof. Chang is a leader in biomedical research and scientific dissemination, actively contributing to academic growth and mentorship.

⚠️ Areas for Improvement:

  1. More Global Recognition
    While well-known in Chinese biomedical circles and respected internationally through publications, increased involvement in global consortia or leadership in international collaborations would further solidify his global scientific footprint.

  2. Public/Community Science Engagement
    Enhancing visibility through public lectures, science communication platforms, or policy advisory roles could broaden the societal impact of his work.

  3. Data-Sharing and Open Science Practices
    Encouraging or highlighting open-access datasets, repositories, or reproducible workflows would align with best practices in modern cell communication research.

🎓 Education:

Professor Zhijie Chang began his academic journey at Northwestern Agricultural University in Yangling, China, where he earned his B.Sc. (1978–1982) in Animal Science. He then continued at the same institution to obtain a combined M.Sc. and Ph.D. in Animal Genetics and Breeding from 1982 to 1989. His graduate research laid the foundation for his future in molecular biology, signaling studies, and genetics. Seeking international exposure and advanced training, he undertook postdoctoral research from March 1997 to October 1998 at the University of Alabama at Birmingham, USA, in the Department of Pathology. There, he specialized in the BMP signaling pathway, gaining expertise in molecular signaling processes critical to cell communication. This blend of domestic and international education has equipped Dr. Chang with both the technical rigor and global perspective needed to pioneer breakthroughs in biomedical science.

💼 Professional Experience:

Professor Zhijie Chang has held a full professorship at Tsinghua University’s School of Medicine since June 2005, where he investigates cancer-related signaling mechanisms. Before this, he completed postdoctoral research at the University of Alabama at Birmingham, focusing on BMP signaling, which strengthened his understanding of developmental and pathological cell signaling. Over the years, he has built a highly productive research lab, contributed extensively to translational medicine, and trained numerous doctoral and postdoctoral researchers. As an editor of FEBS Letters, he also contributes to scientific publishing and peer-review processes. His roles across academia, research, and editorial boards mark him as a multifaceted scientist whose work bridges laboratory insights and therapeutic applications. His collaborative style and consistent research funding reflect his leadership and innovation in molecular oncology and regenerative medicine.

🏅 Awards and Honors:

Professor Zhijie Chang has been recognized multiple times by the Chinese Cell Biology Society for his high-impact publications. In 2003, he received the First Merit Paper Award for his groundbreaking research on hSef-mediated MAPK signaling inhibition in J. Biol. Chem. In 2005, he earned the Third Merit Paper Award for his study on CHIP-mediated degradation of Smad proteins, published in Mol. Cell. Biol.. These awards underscore his early and sustained contributions to deciphering molecular signaling pathways involved in cell communication, differentiation, and oncogenesis. His recent recognitions include publications in top-tier journals like Nature Communications, Molecular Cancer, and Signal Transduction and Targeted Therapy, indicating the continued relevance and innovation of his work. His role as an editor for FEBS Letters further highlights his stature in the field and dedication to advancing cell biology research at national and international levels.

🔬 Research Focus:

Dr. Zhijie Chang’s research primarily investigates cellular communication in cancer and inflammatory diseases, with a focus on CREPT, Smad proteins, and extracellular vesicles. His work dissects how tumor-derived signals modulate the tumor microenvironment, metastasis, and immune cell behavior. He has made critical discoveries regarding the role of CREPT in chromatin looping and transcriptional regulation, especially in triple-negative breast cancer. In pulmonary fibrosis models, he has shown how umbilical cord-derived mesenchymal stem cells (MSCs) modulate macrophage activity via secreted vesicles. Another major area is his exploration of Smurf1, PDK1–Akt, and JAK/STAT3 signaling axes, targeting them for therapeutic intervention in various cancers. His translational approach integrates gene therapy, stem cell-based treatments, and protein signaling studies, bridging basic and clinical sciences. Through collaborative and interdisciplinary methods, Dr. Chang contributes valuable insights into how cells communicate and respond in disease settings.

📚 Publication Top Notes:

  1. 📘 CREPT is required for the metastasis of triple-negative breast cancer through a co-operational-chromatin loop-based gene regulation

  2. 🧪 Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment

  3. 🧬 Gene Therapy with Enterovirus 3C Protease: A Promising Strategy for Various Solid Tumors

  4. 🌬 Umbilical cord-derived mesenchymal stem cells preferentially modulate macrophages to alleviate pulmonary fibrosis

  5. CREPT upregulates the antioxidant genes via activation of NF-κB/Nrf2 in acute liver injury

  6. 🔁 An oncoprotein CREPT functions as a co-factor in MYC-driven transformation and tumor growth

  7. 🎯 Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer

  8. 📤 Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization

  9. 🔋 Oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine

  10. 🍄 Lachnochromonin, a fungal metabolite from Lachnum virgineum, inhibits cell growth and promotes apoptosis in tumor cells through JAK/STAT3 signaling

🧾 Conclusion:

Professor Zhijie Chang exhibits a robust and well-established career built on investigating mechanisms of cell signaling, tumor microenvironment dynamics, and intercellular communication. His scientific rigor, translational impact, and leadership in the field of cell communication make him an outstanding candidate for the Research for Cell Communication Award. Addressing some broader outreach and open science practices could further elevate his profile, but his contributions to foundational and applied research in this domain are already exemplary.

Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Mr. Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Mr. Wei Xue , Renji Hospital, School of Medicine, Shanghai Jiaotong University , China

Dr. Xue Wei, M.D., Ph.D., is a distinguished urologist, professor, and researcher specializing in genitourinary oncology. Currently serving as the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, he also leads its Department of Urology. With over 150 publications, including 100+ SCI-indexed papers, Dr. Xue is a leading expert in minimally invasive urological surgeries, particularly robotic-assisted procedures. He has made significant contributions to prostate cancer treatment and multidisciplinary approaches for metastatic prostate cancer. Dr. Xue is an executive member of various prestigious medical organizations, including the Chinese Medical Association and the European Association of Urology. His groundbreaking research and clinical excellence have earned him multiple accolades, including “Shanghai Leading Talent” and “Outstanding Academic Leader.” With a strong dedication to advancing medical technology and patient care, Dr. Xue continues to shape the future of urological oncology through his pioneering work in surgery, research, and mentorship.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contributions 📚 – Dr. Xue Wei has over 150 publications, including 100+ SCI-indexed papers, highlighting his impactful work in genitourinary oncology.

  2. Leadership & Influence 🌍 – As Vice President of Renji Hospital and Director of Urology, he plays a crucial role in shaping the future of urological research and treatment.

  3. Clinical Expertise 🏥 – He is an expert in robot-assisted and minimally invasive surgeries, particularly nerve-sparing radical prostatectomy and multidisciplinary management of metastatic prostate cancer.

  4. High-Impact Research Grants 💰 – Principal investigator for 12 key research projects, including those funded by the National Natural Science Foundation of China.

  5. Prestigious Recognitions 🏆 – Titles like Shanghai Leading Talent and Outstanding Academic Leader reflect his excellence in academia and clinical practice.

📌 Areas for Improvement:

  1. Citations & Impact Factor Growth – While his publication count is high, increasing citations and impact factor of his papers would further establish global recognition.

  2. Global Collaboration – Expanding international partnerships and multicenter clinical trials could enhance his research influence beyond China.

  3. Innovative Breakthroughs – While excelling in robotic-assisted surgery, pioneering novel therapeutic strategies could further elevate his status as a global thought leader.

🎓 Education:

Dr. Xue Wei completed his M.D. and Ph.D. in Urology at Shanghai Jiao Tong University School of Medicine, a premier institution in China known for its rigorous medical training and research excellence. He further honed his expertise through international academic collaborations, including a tenure as a Visiting Associate Professor at the MD Anderson Cancer Center, USA. His academic journey was marked by intensive research in genitourinary oncology, robotic-assisted surgeries, and advanced treatment modalities for prostate and renal cancers. Over the years, he has received advanced training in minimally invasive urological surgery, leveraging cutting-edge technology to improve surgical outcomes. His strong academic foundation, combined with a commitment to innovation, has made him a globally recognized expert in urological oncology. Through continuous education and research leadership, Dr. Xue remains at the forefront of medical advancements, ensuring his contributions have a lasting impact on both clinical practice and scientific research.

💼 Experience:

Dr. Xue Wei boasts a distinguished career spanning decades in clinical practice, research, and academic leadership. He is the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Director of its Department of Urology. As a key figure in the Chinese and international urology communities, he holds executive positions in prestigious organizations such as the Chinese Medical Association, European Association of Urology, and American Urological Association. Dr. Xue specializes in minimally invasive and robotic-assisted urological surgeries, pioneering advanced techniques in radical prostatectomy and cancer treatment. His leadership extends to mentoring doctoral students and overseeing high-impact research projects funded by national and municipal grants. His role as a principal investigator in groundbreaking studies has led to over 150 peer-reviewed publications. With his clinical expertise, surgical innovations, and research contributions, Dr. Xue remains a leader in shaping the future of urological oncology.

🏆 Awards & Honors:

Dr. Xue Wei has earned numerous prestigious accolades in recognition of his contributions to urological research and clinical excellence. Among his most notable honors are:

  • Shanghai Leading Talent 🌟

  • Outstanding Academic Leader, Shanghai 🏅

  • Shanghai Medical Leading Talent 🎖️

  • Shanghai Craftsman & Shanghai Medical Craftsman 🏆

As a globally recognized expert, Dr. Xue’s pioneering work in robotic-assisted surgery and genitourinary oncology has solidified his reputation as a leading academician and clinician. His dedication to advancing minimally invasive surgery and cancer treatment has not only influenced medical practice in China but also gained international recognition. He serves as a mentor and research leader, shaping the next generation of urologists. With his exceptional achievements, Dr. Xue continues to set benchmarks in urological science, making him a strong contender for the Best Academic Researcher Award.

🔬 Research Focus:

Dr. Xue Wei’s research primarily focuses on genitourinary oncology, with a particular emphasis on prostate cancer, kidney cancer, and minimally invasive surgery. He has led multiple high-impact studies on robot-assisted laparoscopic procedures, multidisciplinary management of metastatic prostate cancer, and biomolecular mechanisms of cancer progression. His work in precision medicine and targeted therapies has contributed to advancements in prostate cancer treatment, enhancing survival outcomes and treatment efficacy.

As the principal investigator of 12 research projects funded by the National Natural Science Foundation of China and the Shanghai Municipal Education Commission, Dr. Xue has pushed the boundaries of medical innovation. His recent research explores the role of m6A RNA modifications, immunotherapy, and cancer stem cells in drug resistance and tumor aggressiveness. His contributions have transformed clinical practices, bridging the gap between cutting-edge research and real-world patient care, making him a global leader in urological oncology research.

📚 Publications Top Notes:

  1. AGD1/USP10/METTL13 Complexes Enhance Cancer Stem Cells Proliferation and Diminish the Therapeutic Effect of Docetaxel 🔬🧬

  2. Specific Activation of cGAS-STING Pathway by Manganese-Doped Bioactive Glasses for Boosting Systemic Tumor Immunotherapy 🏥🧪

  3. Osalmid Sensitizes Clear Cell Renal Cell Carcinoma to Navitoclax Through a STAT3/BCL-XL Pathway 🏥💊

  4. Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer 🔎⚕️

  5. Open Nephron-Sparing Surgery Strategy for Renal Angiomyolipoma with Vena Cava Thrombus 🏥🔬

  6. A Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma 💉🔬

  7. Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in East Asian vs. Non-East Asian Men 🧬🧑‍⚕️

  8. Iron-Loaded Cancer-Associated Fibroblasts Induce Immunosuppression in Prostate Cancer 🩸🛡️

  9. A Multi-Classifier System Integrated by Clinico-Histology-Genomic Analysis for Predicting Recurrence of Papillary Renal Cell Carcinoma 🏥📊

🏅 Conclusion:

Dr. Xue Wei is a highly suitable candidate for the Best Academic Researcher Award due to his exceptional contributions in urological oncology, leadership in clinical research, and dedication to innovation. His extensive academic output, surgical expertise, and impact on medical education make him a leading figure in his field. Enhancing global collaborations and high-impact publications would further solidify his legacy as a world-class researcher. 🚀